Stockscreener 앱 받기
16.40
1.11%
0.18
전일 마감가:
$16.22
열려 있는:
$16.2
하루 거래량:
5,517
Relative Volume:
0.29
시가총액:
$87.13M
수익:
$858.00K
순이익/손실:
$-7.82M
주가수익비율:
-11.31
EPS:
-1.4503
순현금흐름:
$-27.59M
1주 성능:
-2.24%
1개월 성능:
-3.07%
6개월 성능:
+91.81%
1년 성능:
+265.48%
1일 변동 폭
$16.20
$16.41
1주일 범위
$16.16
$16.62
52주 변동 폭
$3.6701
$17.57
Rallybio Corp Stock (RLYB) Company Profile
명칭
Rallybio Corp
전화
203- 859-3820
주소
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
16.40 | 87.13M | 858.00K | -7.82M | -27.59M | -1.4503 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-17 | 개시 | H.C. Wainwright | Buy |
| 2023-04-10 | 개시 | Wedbush | Outperform |
| 2022-12-09 | 개시 | JP Morgan | Overweight |
| 2022-02-22 | 개시 | JMP Securities | Mkt Outperform |
| 2021-08-23 | 개시 | Cowen | Outperform |
| 2021-08-23 | 개시 | Evercore ISI | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
모두보기
Rallybio Corp 주식(RLYB)의 최신 뉴스
Form 4 Rallybio Corp: Helen M. Boudreau (Director) For: 16 October - Investing.com Canada
Rallybio Corp SEC Filing (Oct 16, 2026) - Stock Titan
Form 4 Rallybio Corp: Robert Lorne Hopfner (Director) For: 12 October - Investing.com India
Form 4 Rallybio Corp: Robert Lorne Hopfner (Director) For: 12 October - Investing.com Nigeria
Form 4 Rallybio Corp: Robert Lorne Hopfner (Director) For: 12 October - Investing.com UK
A $215M financing would split ownership three ways in Rallybio (Nasdaq: RLYB)'s proposed Avenzo merger. - Stock Titan
Form 4 Rallybio Corp: Jonathan I. Lieber (CFO) For: 9 October - Investing.com Nigeria
Form 4 Rallybio Corp For: 9 October By Investing.com - Investing.com South Africa
Form 4 Rallybio Corp For: 9 October By Investing.com - Investing.com Nigeria
Form 4 Rallybio Corp For: 9 October By Investing.com - Investing.com UK
Form 4 Rallybio Corp For: 2 October By Investing.com - Investing.com Nigeria
Form 4 Rallybio Corp For: 2 October By Investing.com - Investing.com South Africa
The proposed Avenzo merger would pair $215M financing with an ownership split for Rallybio (RLYB) holders. - Stock Titan
Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com South Africa
Form 4 Rallybio Corp For: 28 September - Investing.com India
Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com Australia
Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com Nigeria
Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com UK
Rallybio (NASDAQ: RLYB) holders expected to own 2.8% of new Avenzo - Stock Titan
Rallybio (NASDAQ: RLYB) Announces CFO Jonathan Lieber's Shift to Part-Time Role Starting September 15, 2026 - Kalkine Media
Rallybio's Jonathan Lieber to Shift to Part-Time CFO Role - TradingView
Rallybio Corp (RLYB) Debt 2025 - Stock Titan
Balyasny Asset Management L.P. Exits Rallybio Corp (RLYB) Stake in 13DG Filing - GuruFocus
Rallybio (RLYB) Holds Near $17 Ceiling as Traders Weigh Breakout PotentialWave Extension - vinanet.vn
Rallybio Company Profile & Introduction - Moomoo
Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen - MarketBeat
Rallybio Corporation (RLYB) holders report 3.56% stake in Schedule 13G/A - Stock Titan
Cormorant Asset Management (RLYB) now reports 0% beneficial ownership of Rallybio - Stock Titan
RLYB Q1 2026 Earnings: Wider-than-Expected Loss Underscores Cost of Advancing Rare-Disease PipelineEBITDA Estimate Trend - vinanet.vn
Rallybio Corporation (NASDAQ:RLYB) Sees Large Drop in Short Interest - MarketBeat
Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A - Stock Titan
Rallybio Corp (NASDAQ: RLYB) Stock Price, News & Analysis - Kalkine
RLYB Q1 2026 Earnings: Wider Loss Highlights Acceleration of Clinical-Spend Run-RateGuidance vs Actual - vinanet.vn
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS - MarketBeat
Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC reports 15% Rallybio Corp (RLYB) stake, including 5% fund holding - Stock Titan
Rallybio Corp 2Q 2026: Revenue $0 Net income $43.67M, EPS $7.53— 10-Q Summary - TradingView
Laurion Capital exits Rallybio (RLYB) position, reports 0% beneficial ownership - Stock Titan
Rallybio Q1 2026 Earnings: Wider-than-Expected Loss as Development Costs PersistGeographic Revenue Trends - dars.gov.et
Rallybio Q1 2026 Earnings: Wider-than-Expected Loss as Development Costs PersistRevenue Miss Report - vinanet.vn
RLYB|Rallybio Corp|Price:16.350|Chg%:+0.160 - TradingKey
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Balance Sheet - TradingKey
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest - MarketBeat
RLYB|Rallybio Corp|Price:16.160|Chg%:-0.150 - TradingKey
Rallybio Market Sentiment - Benzinga España
Rallybio Corp (RLYB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rallybio Corp 주식 (RLYB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Boudreau Helen M | Director |
Oct 16 '26 |
Option Exercise |
15.28 |
2,062 |
31,507 |
8,604 |
| Hopfner Robert Lorne | Director |
Oct 12 '26 |
Option Exercise |
7.41 |
14,820 |
109,875 |
14,820 |
| Lieber Jonathan I | Chief Financial Officer |
Oct 09 '26 |
Option Exercise |
6.08 |
3,910 |
23,773 |
13,650 |
| Uden Stephen | Chief Executive Officer |
Oct 06 '26 |
Option Exercise |
6.08 |
22,456 |
136,532 |
115,620 |
| Lieber Jonathan I | Chief Financial Officer |
Sep 29 '26 |
Option Exercise |
6.08 |
5,000 |
30,400 |
9,740 |
| Liu Hui | Director |
Sep 24 '26 |
Option Exercise |
6.06 |
12,044 |
72,941 |
12,044 |
| Chung Wendy | Director |
Sep 16 '26 |
Option Exercise |
2.38 |
3,562 |
8,478 |
3,562 |
| Boudreau Helen M | Director |
Jul 06 '26 |
Option Exercise |
2.38 |
3,562 |
8,478 |
6,542 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 19 '26 |
Buy |
13.98 |
10,200 |
142,582 |
926,352 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 18 '26 |
Buy |
13.98 |
6,009 |
83,981 |
916,152 |
0.68%
3.98%
자본화:
|
볼륨(24시간):